Pancreatic cancer is a relatively common digestive system tumor with a high degree of malignancy. More than half of PCs are located in the head of the pancreas, and about 90% are ductal adenocarcinomas originating from the ductal epithelium. The five-year survival rate after PC is diagnosed is about 10%, and it is one of the malignant tumors with the worst prognosis. Therefore, new effective therapies are urgently needed to improve the low survival rate of patients with advanced PC. PC patients require continued targeted chemotherapy. Tumor cells isolated from human tissues can be used to predict patients' response to chemotherapy and can also be used in the pathogenesis of PC and the development of drugs and therapies.
Pancreatic Cancer Cell Lines We Offer
Pancreatic cancer may originate from the exocrine or endocrine compartment of the pancreas, and most of them are exocrine tumors, divided into ductal adenocarcinoma and acinar adenocarcinoma; endocrine tumors are mainly pancreatic neuroendocrine tumors. There are differences between exocrine and endocrine tumors, and Alfa Cytology can select the most appropriate cell line for you.
Alfa Cytology is a leading global life sciences company. We have in-depth knowledge of PC units and other components. Here, we are committed to providing diverse cell lines for PC research and development of successful treatment options. If you are interested in our services, please feel free to contact us. We will provide professional and competitively priced solutions tailored to your needs.
PANC-1 Cell Line Human
Origin: Human caucasian pancreas
Description: Ductal pancreatic cancer arising from a 56-year-old white male. Cells have a G6PD type B phenotype. When tested at ECACC, the Y chromosome was undetectable in this cell line by short tandem repeat (STR)-PCR analysis. Due to the genetic instability of cancer cell lines, the Y chromosome may be rearranged or lost, resulting in undetectability. Based on STR-PCR analysis, this cell line was of the same origin as that provided by the depositor.
PSN1
Origin: Human pancreatic adenocarcinoma
Description: Human pancreatic cancer cell line PSN1 was derived from pancreatic adenocarcinoma tissue. After transplantation into nude mice, a PSN1 cell line was established from the xenografts. What is unique about PSN1 cells is the extent of amplification of c-myc (50-fold) and activated c-Ki-ras (3-6-fold) with a point mutation from GGT to CGT at codon 12 Same as PSN1 cells. Primitive tumors and contained increased amounts of c-myc and c-Ki-ras transcripts. Loss of one of the two p53 alleles and a point mutation from AAG to CAG at codon 132 in the remaining allele were also observed in PSN1.
AR42J
Origin: Rat exocrine pancreatic tumour
Description: Transplantable tumors derived from rat exocrine pancreas. This strain is tumorigenic in nude mice and shows significant secretion of amylase and other exocrine enzymes.
HaP-T1
Origin: Hamster syrian adenocarcinoma
Description: Derived from an adenocarcinoma of the pancreas of a Syrian Golden hamster (GN strain).
HuP-T3
Origin: Human pancreatic adenocarcinoma
Description: Ascitic fluid sample obtained from a 66-year-old Japanese man with poorly differentiated pancreatic cancer.
HuP-T4
Origin: Human pancreatic adenocarcinoma
Description: Ascitic fluid sample obtained from a 60-year-old Japanese man with well-differentiated pancreatic cancer.
TGP 49
Origin: Mouse pancreatic acinar carcinoma
Description: TGP 49 has been isolated from acinar cell carcinomas arising in the pancreas of transgenic Tg(E1a-1-SV40E)Bri18 mice. These mice carry a pseudogene construct consisting of a pancreatic-specific elastase 1 promoter linked to the SV40T antigen, thereby representing an animal model of pancreatic carcinogenesis. TGP 49 secretes small amounts of somatostatin and is one of a series of cell lines isolated from pancreatic tumors deposited at ECACC. They are reported not to secrete amylase or lipase but do secrete trypsin.
DSL6A/C1
Origin: Rat pancreatic carcinoma
Description: DSL6A/C1 is derived from transplantable acinar cell carcinoma (DSL-6) established from primary pancreatic cancer in diazaserine-treated Lewis rats. Expression of the ductal cell marker OC.2 is shown along with subpopulations expressing the ductal markers OV-6, CK-7, and CK-19. DSL6A/C1 cells have been reported to be tumorigenic in Lewis rats and produce solid tumors composed of duct-like structures surrounded by dense fibrous tissue. This cell line lost structural and immunohistochemical acinar cell markers during culture and retransplantation, while acquiring ductal cell markers.
AsPC-1
Origin: Human pancreas adenocarcinoma ascites metastasis
Description: The cell line was derived from a nude mouse xenograft that was started with cells from the ascites of a 62-year-old female Caucasian patient with pancreatic cancer. These cells produce carcinoembryonic antigen (CEA), human pancreas-related antigen, human pancreas-specific antigen, and mucins.
CFPAC-1
Origin: Human caucasian pancreatic adenocarcinoma
Description: CFPAC-1 is a ductal pancreatic adenocarcinoma that was generated by differential trypsin digestion of explant cultures of liver metastatic lesions in a 26-year-old white man with cystic fibrosis (CF). This cell line expresses cystic fibrosis transmembrane regulator (CFTR) and has ion transport properties consistent with CF deficiency. CFPAC-1 cells display epithelial morphology and polarization, with apical microvilli. Expression of cytokeratin and carcinoembryonic antigen characteristic of pancreatic duct cells has been described. These cells express the CF gene and display the most common CF mutation, a deletion of three nucleotides resulting in the deletion of phenylalanine 508. CFPAC-1 cells are also tumorigenic in nude mice.
CRI-G5
Origin: Rat NEDH islet tumour
Description: Established from transplantable islet cell tumors in NEDH rats. The cells secrete insulin and glucagon. This cell line can be used in place of CRI-D11.
CRI-D11
Origin: Rat NEDH islet tumour
Description: Established from a NEDH rat transplantable islet cell tumour. The cells secrete insulin and glucagon.
CRI-D2
Origin: Rat NEDH islet tumour
Description: Established from a NEDH rat transplantable islet cell tumour. The cells secrete insulin and glucagon.
TGP 52
Origin: Mouse islet cell tumour
Description: TGP 52 has been isolated from islet tumors arising in the pancreas of transgenic Tg (E1a-1-SV40E) Bri18 mice. These mice carry a pseudogene construct consisting of a pancreatic-specific elastase 1 promoter linked to the SV40T antigen, thereby representing an animal model of pancreatic carcinogenesis. TGP 52 cells are SV40T antigen positive and secrete somatostatin and are one of a series of pancreatic tumor lines deposited at ECACC. The cells briefly produce insulin in culture and then somatostatin.
TGP 54
Origin: Mouse pancreatic islet cell tumour
Description: TGP 54 was isolated from islet tumors arising in the pancreas of transgenic Tg(E1a-1-SV40E)Bri8 mice. These mice carry a pseudogene construct consisting of a pancreatic-specific elastase 1 promoter linked to the SV40T antigen, thereby representing an animal model of pancreatic carcinogenesis. TGP 54 cells are SV40T antigen-positive, secrete small amounts of somatostatin, and are one of a series of cells obtained from pancreatic tumors deposited at ECACC.
TGP 55
Origin: Mouse pancreatic small cell anaplastic carcinoma
Description: TGP 55 has been obtained from a small cell anaplastic carcinoma arising in the pancreas of a transgenic Tg(Ela-1SV40E)Bri 18 mouse these mice carry a pseudogene construct composed of a pancreatic-specific elastase-1 promoter linked to the coding region for SV40 T antigen and thereby represent an animal model for pancreatic carcinogenesis. TGP 55 cells are SV40T antigen positive and secrete somatostatin, it is one of a series of cell lines isolated from pancreatic tumours deposited at ECACC. Cells secrete somatostatin and insulin in culture. Adherent clumps of small cells.
RIN-m
Origin: Rat islet cell tumour
Description: Established from transplantable pancreatic tumors in the islets of Langerhans. The tumor originated in irradiated NEDH-suppressed albino rats and was maintained by serial transplantation of Nedh rats. The cell line RIN-m was established from the fourth nude mouse xenograft after transplantation into athymic nude mice, and 9 days after tumor resection, the cells were exposed to cystine-free medium, resulting in complete elimination of fibroblasts. RIN-m cells secrete insulin and somatostatin. High levels of levodopa decarboxylase and membrane-bound secretory granules were detected. RIN-5F (95090402) was established as a secondary clone of RIN-m.
RIN-5F
Origin: Rat islet cell tumour
Description: RIN-5F is a secondary clone of the rat islet tumor cell line RIN-m (Sigma catalog number 95071701). Cloning was performed by limiting dilution in RPMI 1640, 10% FBS, and 20% conditioned medium. Conditioned medium contains growth hormone and prolactin produced by rat pituitary tumor cells GH3. RIN-5F cells secrete insulin, produce high levels of the key APUD enzyme, L-dopa decarboxylase, and contain membrane-bound secretory granules.
MIA-Pa-Ca-2
Origin: Human Caucasian pancreatic carcinoma
Description: Established cell lines from undifferentiated human pancreatic cancer. The tumor was obtained from a 65-year-old Caucasian male. These cells are large, have abundant cytoplasm, exhibit a high degree of aneuploidy, and have a tendency to grow on top of other cells, eventually growing freely in suspension. Sensitive to L-asparaginase.
BXPC3 Cell Line Human
Origin: Human primary pancreatic adenocarcinoma
Description: From a 61-year-old woman with primary pancreatic adenocarcinoma. BxPC-3 cells produce mucin and produce tumors in nude mice that are moderately to poorly differentiated like primary adenocarcinomas.